Guardant Health (GH)
Blood and tissue cancer tests spanning screening, monitoring, and treatment selection.
Something off on this page? Send us feedback.
Provides blood- and tissue-based cancer tests for screening, recurrence monitoring, therapy response, and treatment selection, alongside data and development services for drugmakers. Clinical test revenue is concentrated in the United States, where adoption depends on regulatory clearance, treatment guidelines, and payer coverage.
Provides cancer testing across screening, recurrence monitoring, therapy response, and treatment selection. Guardant360 Liquid CDx and Guardant360 Tissue profile advanced tumors from blood or tissue; Guardant Reveal detects residual or recurring disease and tracks treatment response; Shield screens average-risk adults for colorectal cancer. A shared Smart Platform applies genomic, epigenomic, and RNA data across the portfolio.
Sells clinical tests mainly through U.S. oncology, primary-care, and health-system channels, while laboratory partners and distributors extend access internationally. GuardantINFINITY, GuardantOMNI, and GuardantINFORM support biopharmaceutical research, companion-diagnostic development, and analysis of real-world test data. Commercial adoption depends on clinical evidence, regulatory status, treatment-guideline inclusion, and reimbursement from government and commercial payers; some offerings remain laboratory-developed tests subject to evolving oversight.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 10, 2026 | Bernstein | Reiterate | Rating: —Target: $200 | Target: $210 |
| Sep 9, 2026 | UBS | Reiterate | Rating: —Target: $150 | Target: $225 |
| Sep 8, 2026 | Redburn Partners | Target | Target: — | Target: $203 |
| Aug 4, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $175 | Target: $185 |
| Aug 4, 2026 | Stephens | Reiterate | Rating: —Target: $99 | Target: $195 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.05B · Total debt $1.70B · Total assets $1.91B · Shareholders' equity −$222.9M
- Revenue
- $335.0M
- Operating income
- −$129.1M
- Net income
- −$120.1M
No dividends on record.
| Institutions | ≈ 97.31% | 130.59M shares | |
|---|---|---|---|
| 625 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.88% | 3.86M shares | |
| 18 holders · as of Sep 22, 2026 | |||
| Adds to | 100.19% | ||
134.20M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 100.19%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 5.68% | 7.62M | as of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 4.85% | 6.51M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.29% | 5.76M | as of Jun 30, 2026 |
FMR LLCInstitution | 4.09% | 5.49M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 4.06% | 5.45M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2026 | Musa Tariq | director | −116 | $175.00 |
| Sep 16, 2026 | Alex M. II Azar | director | −826 | $175.00 |
| Sep 16, 2026 | Steve E. Krognes | director | −6,674 | $175.74 |
| Sep 15, 2026 | Darya Chudova | officer: Chief Technology Officer | −7,738 | $178.00 |
| Sep 11, 2026 | Kumud Kalia | officer: Chief Information Officer | −4,000 | $158.05 |
- Natera
The primary head-to-head rival in post-surgical MRD monitoring for solid tumors.
- Tempus AI
AI oncology diagnostics in CGP, liquid biopsy, and MRD — sued by Guardant.
- Caris Life Sciences
WES/WTS CGP and single Assure blood platform for therapy selection, MRD, MCED.
- GRAIL
Galleri multi-cancer early detection blood test overlapping the screening slot.
- NeoGenomics
Cancer-genetics lab entering liquid biopsy CGP with PanTracer LBx (July 2025).
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Guardant Health | $177.13 | −0.02% | $23.77B | — | — | 20.1 | +44.3% |
| Natera | $390.30 | −0.15% | $55.98B | — | — | 20.7 | +37.7% |
| Tempus AI | $77.00 | −0.25% | $13.52B | — | — | 9.4 | +21.6% |
| Caris Life Sciences | $31.35 | −0.39% | $8.90B | 87.9 | 124.5 | 9.0 | +45.4% |
| GRAIL | $108.52 | +0.51% | $4.66B | — | — | 28.2 | +25.7% |
| NeoGenomics | $18.71 | −0.98% | $485.4M | — | 67.3 | 0.6 | +11.2% |
| Median | 87.9 | 95.9 | 9.4 | +25.7% |